Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
No active IND (Investigational New Drug application) is publicly listed in the United States as of 2025
The planned number of 12 subjects (six per each dose group A and B) having completed SAR425899 treated and evaluated for PET receptor occupancy was not achieved in this study
Key findings: No increased thyroid cancer risk versus any comparator Consistent findings across multiple subgroups Multiple comparator groups reduce artifact risk JAMA Otolaryngology Analysis High-profile paper directly addressing how detection bias and healthcare utilization create apparent diagnosis increases that aren't causal
Indeed, higher circulating concentrations of IGF-1 were related to increased survival in ALS mouse model 21
US$ 21.61
US$ 25.88
US$ 23.21
US$ 23.16
US$ 21.82
US$ 28.95
US$ 23.18
US$ 23.98
US$ 28.88
US$ 21.44
US$ 29.44
US$ 25.81
US$ 28.37
US$ 28.37
